|
|
Volumn 28, Issue 11, 2010, Pages 1137-1138
|
|
Bristol-Myers Squibb reaps biologics in ZymoGenetics windfall
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATACICEPT;
BIOLOGICAL PRODUCT;
BOCEPREVIR;
INSULIN;
INTERLEUKIN 29;
MACROGOL;
PEGINTERFERON;
RECOMBINANT BLOOD CLOTTING FACTOR 7A;
RECOMBINANT CYTOKINE;
RECOMBINANT INTERLEUKIN 21;
RECOTHROM;
RIBAVIRIN;
TELAPREVIR;
THROMBIN;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
FUNDING;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
MELANOMA;
METASTASIS;
NOTE;
PRIORITY JOURNAL;
BIOLOGICAL PRODUCTS;
CLINICAL TRIALS AS TOPIC;
DRUG DISCOVERY;
DRUG INDUSTRY;
HUMANS;
PATENTS AS TOPIC;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 78149330186
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1110-1137 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
